132 related articles for article (PubMed ID: 7301655)
1. The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer.
Killian CS; Vargas FP; Pontes EJ; Beckley S; Slack NH; Murphy GP; Chu TM
Prostate; 1981; 2(2):187-206. PubMed ID: 7301655
[TBL] [Abstract][Full Text] [Related]
2. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
[TBL] [Abstract][Full Text] [Related]
3. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer.
Killian CS; Emrich LJ; Vargas FP; Yang N; Wang MC; Priore RL; Murphy GP; Chu TM
J Natl Cancer Inst; 1986 Feb; 76(2):179-85. PubMed ID: 2418245
[TBL] [Abstract][Full Text] [Related]
4. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum alkaline phosphatase isoenzyme levels in advanced prostatic carcinoma.
Wajsman Z; Chu TM; Bross D; Saroff J; Murphy GP; Johnson DE; Scott WW; Gibbons RP; Prout GR; Schmidt JD
J Urol; 1978 Feb; 119(2):244-6. PubMed ID: 633486
[TBL] [Abstract][Full Text] [Related]
6. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
[TBL] [Abstract][Full Text] [Related]
7. Isoenzymes of alkaline and acid phosphatases as bones metastasis marker in breast cancer patients.
Desoize B; Veiler V; Pourny C; Comoe L; Jardillier JC
Anticancer Res; 1989; 9(4):1105-9. PubMed ID: 2817792
[TBL] [Abstract][Full Text] [Related]
8. Plasma acid and alkaline phosphatase in patients with breast cancer.
Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
[TBL] [Abstract][Full Text] [Related]
9. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
[TBL] [Abstract][Full Text] [Related]
10. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A
Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127
[TBL] [Abstract][Full Text] [Related]
11. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
12. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of two serum isoenzyme phosphatases as bone metastasis markers].
Desoize B; Pourny C; Amico S; Larbre H; Jardillier JC
Bull Cancer; 1990; 77(12):1211-21. PubMed ID: 2081281
[TBL] [Abstract][Full Text] [Related]
14. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
[TBL] [Abstract][Full Text] [Related]
15. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
Kida T; Higuchi Y
Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
[TBL] [Abstract][Full Text] [Related]
16. Clinical study on prognosis of metastatic prostate cancer based on extent of disease on pretreatment bone scintigraphy.
Fuse H; Mizuno I; Yokoyama T; Sakamoto M; Katayama T
Int Urol Nephrol; 1995; 27(5):567-74. PubMed ID: 8775041
[TBL] [Abstract][Full Text] [Related]
17. [Tumor markers in cancer of the prostate].
Nogueira March JL; Ojea A; Jamardo D; Figueiredo L; Diez E; PĂ©rez Villanueva J
Actas Urol Esp; 1985; 9(1):79-82. PubMed ID: 4013850
[No Abstract] [Full Text] [Related]
18. Bone scanning and plasma phosphatases in carcinoma of the prostate.
O'Donoghue EP; Constable AR; Sherwood T; Stevenson JJ; Chisholm GD
Br J Urol; 1978 May; 50(3):172-7. PubMed ID: 753455
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
[TBL] [Abstract][Full Text] [Related]
20. Identification of bone and liver metastases from breast cancer by measurement of plasma alkaline phosphatase isoenzyme activity.
Mayne PD; Thakrar S; Rosalki SB; Foo AY; Parbhoo S
J Clin Pathol; 1987 Apr; 40(4):398-403. PubMed ID: 3584482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]